`
`From:
`Sent:
`To:
`Subject:
`
`Dear Nathan Beaver,
`
`Stewart, Kendra <Kendra.Stewart@fda.hhs.gov:~
`Thursday, October 12. 2017 10:54 AM
`Beaver, Nate
`RE: Orange Book Listing Date
`
`Per Orange Book records, the ’507 patent was listed on the Orange Book website on 5f19f2016 and the '240 patent was
`listed on 6l9f2016.
`
`Regards,
`
`CAPT Kendra S. Stewart, R.Ph., Pharm.D.
`us Public Health Service
`Supenrisoc Orange Book Staff
`Center for Drug Evaluation and Research
`Office of Generic Drugs
`U.3. Food and Drug Administration
`Tel: 24D-402-3?9?
`
`ORANGE BOOK QUESTTONS:Wm
`WEBSITE:W
`
`us. FOOD some
`IDHIIIITIIIIOI
`
`DIE."
`
`From:Wm [Want]
`Sent: Wednesday, October 11, 2017 4:25 PM
`To: Stewart, Kendra
`Subject: Orange Book Listing Date
`
`Dr. Stewart.
`
`This fol|0ws up on a voicemail I left you earlier today. We represent United Therapeutics (UT) and are trying to confirm
`the date of publication in the Orange Book [i.e., the date the electronic OB was updated and patent information was
`publicly available} for two US Patents that were submitted by UT:
`
`US Patent Nos. 9,339,507 and 9,358,240
`
`These were submitted for listing by UT on 6f8i'2016 for Tyvaso with respect to the ‘240 patent and on 5f17i'2016 with
`respect to the '50? patent .
`
`I am hoping that Orange Book Staff can confirm this information and respond by email with the actual date of listing in
`the OB.
`
`Thank you.
`
`UNITED THERAPEUTICS. EX. 2030
`WATSON LABORATORIES V. UNITED THERAPEUTICS, IPR201T-fl1621
`Page 1 of2
`
`
`
`Best regards.
`
`Nate
`
`Nathan A. Beaver, Partner
`Foley 8t Lardner LLP — 3000 K St. NW, Suite 600
`Washington, DC 2000?
`{p} 202—295-4039 — If) 202-6?2-5399
`mm
`
`The preceding email message may be confidential or protected by the attomey-client privilege. It is not intended
`for transmission to, or receipt by, any unauthorized persons. If you have received this message in error, please
`(i) do not read it, (ii) reply to the sender that you received the message in error, and (iii) erase or destroy the
`message. Legal advice contained in the preceding message is solely for the benefit of the Foley & Lardner LLP
`client(s) represented by the Firm in the particular matter that is the subject of this message, and may not be
`relied upon by any other party.
`
`UNITED THERAPEUTICS, EX. 2030
`WATSON LABORATORIES V. UNITED THERAPEUTlCS, IPR2017-01621
`Page 2 of 2
`
`